FDA to review Eisai’s Leqembi Iqlik sBLA for Alzheimer’s

Alzheimer’s disease is characterised by amyloid beta and tau pathologies, driven by ongoing neurotoxicity from protofibrils. Credit: StanislavSukhin / Shutterstock.com.



  • Eisai Biogen FDA